6,8a-deoxy-5-oxoavermectin
Bl a, 4'-deoleandrosyl-6,8a-seco-6,8a-deoxy-5-oxoavermectin B2a and 6,8a-seco-6,8a-deoxy-2,5-didehydroavermectin B2a, all of which lack the furari ring at C-6, C-8a. The mutation affecting the formation of the furan ring (aveE) is located in the center of the gene cluster for avermectin biosynthesis.
The avermectins are oleandrose disaccharide derivatives of 16-membered pentacyclic lactones produced by Streptomyces avermitilis^with potent anthelmintic and insecticidal activities. During studies of the biosynthesis of avermectin, some biosynthetically blocked mutants of S. avermitilis have been isolated and characterized. Chen and Inamine2) isolated a mutant which produced 6,8a-deoxy-avermectin derivatives and found that the mutant was deficient in the formation of the furan ring kt C-6 to C-8a on the avermectin aglycone; the mutant accumulates seven avermectin-related compounds in mycelia. Recently, we isolated a recombinant strain of S. avermitilis (K2038) which produces only two components, avermectins Bla and B2a3), which have most potent anthelmintic activity. The recombinant strain possesses two phenotypes; loss of avermectin B2 5-O-methyltransferase activity (aveD, accumulating "B" components) and efficient incorporation of L-isoleucine or its keto acid into the avermectin aglycone (X, accumulating "a" components). Wehave isolated mutants which are unable to form the furan ring from the recombinant strain. This paper deals with mutant isolation, structure elucidation of new compounds from the mutant K2057, and the location of mutation in gene cluster for avermectin biosynthesis.
Materials and Methods Microorganisms 59
Streptomyces avermitilis K2038 derived by protoplast fusion between K2021 and K20343). Mutant K2057 from strain K2O38was used for the isolation of new compounds. Mutagenesis S. avermitilis K2038 was mutagenised with 7V-methyljV'-nitro-TV-nitrosoguanidine as described previously40.
Mutantswere screened by examiningthe mycelial extract of each colony by silica gel TLCor reversed phase HPLC as described previously5' 6).
Media and Fermentation YMSagar4) was used for speculation. Liquid media5) were used for the seed and fermentation culture. Spores of mutant K2057 were inoculated into a 500-ml flask containing 100ml of seed medium and cultured on the rotary shaker (200 rpm) for 2 days at 28°C. Two milliliters of the seed culture was inoculated into a 500-ml flask containing 100 ml of production medium and incubated on the rotary shaker (180rpm) for 7 days at 28°C.
Extraction of Avermectin-related Compounds
Fermentation cultures of sixty-five flasks (6 liters) was filtered to remove the culture filtrate. The residual mycelia were washed with 1 liter ofdeionized water and harvested. One liter of acetone was added to the washed mycelia and mixed vigorously shaking for 30 minutes at room temperature and filtered to removemycelia. The mycelia were reextracted with 500 ml ofacetone and the combined acetone extracts were evaporated under the reduced pressure. Five hundred milliliters of deionized water was added to the concentrate and the mixture was extracted twice with 150ml of methylene chloride and methylene chloride extracts were evaporated to dryness. The oily extract (3.02g) was dissolved in 5.0ml of ethyl acetate, the solution passed through 25g of dry silica gel to removeoily material and the eluate was evaporated to dryness. The crude material (2.43. g) Avermectin-related Compounds Amongover 2,000 colonies obtained after the treatment of S. avermitilis K2038 with TV-methyl-iV'-nitro-7V-nitrosoguanidine, only one colony was found to produce avermectin-related compounds different from avermectins Bla and B2a, the products of the parent strain K2038. The mutant strain was named K2057. As shown in Fig. 1 Culture conditions were described previously4). The myceliumfrom a 10-ml culture was extracted with 5ml of methanol, after removal methanol, products were extracted with 1 ml of chloroform. The organic layer was harvested and evaporated to dryness. The crude mycelial extract was dissolved in methanol. A portion of the extract was analyzed by reversed-phase HPLCas described previously5*.
?z-hexane-2-propanol (85 : 15). Fractions 43~70 contained compounds II and IV (46mg), fractions 74~85 contained compound II (10mg), fraction 86~124
contained compounds I and II (41 mg), and fractions 125^145 contained compound I (31 mg). Finally, each compoundwas isolated from the corresponding partially purified fraction by preparative silica gel TLC using n-hexane-2-propanol (85 : 15) as developing solvent except compoundsV and VII. ofIR absorption at 1675cm x in addition to the lactone carbonyl absorption at 1705cm"1. Mass spectra and elementary analysis support the molecular mass and formula of each compound ( Table 1) .
Structures of Compounds I to VII The structures of these compoundswere determined by comparison of their spectral properties with those of natural avermectins and their derivatives9). The *H and 13C NMRspectra (Tables 2 and 3) were particularly informative. The structures of compounds I, II, III, IV, VI and VII were considered to be similar to those of avermectins B2a, Bla, 4'-deoleandrosylavermectin Bla, B2a, Bla and avermectin Bla aglycone, respectively, based on spectral data. 13C NMRshowed that loss of the oxymethine carbon at C-6 (79.3-79.4ppm ) and oxymethylene carbon at C-8a (68.2-68.3ppm) had occurred in these compounds with addition of the methyl carbon (13.3-14.0ppm) and the methylene carbon (48.0-48.7 ppm). Moreover, new proton signals, 3.44-3.80ppm (2H, m) of H-6 and 1.55-1.77ppm (3H, s) of H-8a, were detected in their XHNMRspectra. These results indicate the absence of a furan ring formed from C-6, C-7, C-8 to C-8a, which is present in the avermectins. The presence of an a,/?-unsaturated ketone in these compoundswas confirmed by gain of a carbonyl carbon (196.3-196.5ppm ) and loss of a proton in the C-5 position. Consequently, compounds I, II and VII were identified with 6,8a-seco-6,8a-deoxyavermectins B2a, Bla and 6,8a-seco-6,8a-deoxy-5-oxo avermectin Bla aglycone, respectively, which had been previously reported2'10). On the other hand, compounds III, IV, V and VI were novel derivatives of avermectins. Compounds III, IV and VI lack one oleandrose moiety and compounds IV and VI contain an a,/?-unsaturated ketone, suggesting that compounds III, IV and VI are new derivatives of avermectins and are 4'-deoleandrosyl-6,8a-seco-6,8a-deoxyavermectin B la, 4'-deoleandrosyl-6,8a-seco-6,8a-deoxy-5-oxoavermectin B2a and 4'-deoleandrosyl-6,8a-seco-6,8a-deoxy-5-oxoavermectin B2a, respectively (Fig. 2) . The structure of compound V was determined by comparison with that of compoundI, 6,8a-seco-6,8a-deoxyavermectin B2a. Their XHand 13C NMRspectra (Fig. 3) were particularly informative.
Two proton signals, C-2-H and C-5-H, and one of two protons at C-6 observed with compound I disappeared, and the other proton appeared in a down field with compoundV. Furthermore, the signals of six carbons at C-2 to C-7 were shifted down field region ( Table 3) . The above results indicate that a 6-membered ring at C-2 to C-7 is aromatized. Ultimately, the structure of compound V was determined as 6,8a-seco-6,8a-deoxy-2,5-didehydroavermectin B2a.
Determination of the Region for the Furan Ring Formation
Step on the Cloned DNAFragment Since all products of mutant K2057 were 6,8a-seco-6,8a-deoxy derivatives of avermectins, the mutant contained mutation(s) affecting furan ring formation at C-6 to C-8a and we defined the genotype as aveE. Wehave cloned entire gene cluster for avermectin biosynthesis6), and cosmid clones were used to determine the location of aveE by complementation of the mutant with wild type DNAfragments to restore avermectin production. The transformants produced avermectins B l a and B2a which were products of the parent strain K2038. As shown in 1.27 (d, 6.0) Spectra were recorded in CDC13solution; chemical shifts are given in ppm; coupling constants are given in hertz.
Abbreviations: a = axial, e = equatorial. * Unresolved in spectra. Fig. 4(A) , seven cosmid clones were introduced into mutant K2057; transformants derived from four different cosmids produced avermectins Bla and B2a. Since the 4.9 kbp BamHlfragment in the middle of the gene cluster for avermectin biosynthesis overlapped in these cosmid (Fig. 4(B) ).
Two of the transformants carrying the 4.90 kbp BamRI or 3.15kbp PstI fragments produced abundant avermectins Bla and B2a, however, transformants carrying Opencolumn; complementationwas not observed, closed column; complementationwas strongly observed and hatched column; complementationwasobserved but the restoration of avermectin production was not enough.
2.25 kbp Nsil/BamHI fragment produced 6,8a-seco-6,8a-deoxy derivatives of avermectins and small amount of avermectins Bla and B2a (Fig. 4(B) ).
Discussion
Mutants affecting furan ring formation at C-6 to C-8a in the avermectins have been reported by Chen and Inamine2) and Goegelman et al.10 ).
MA-5218, which was derived from the wild type strain S. avermitilis ATCC31271, produced at least seven 6,8a-seco-6,8a-deoxyavermectin derivatives10). On the other hand, we obtained mutant K2057affecting furan ring formation derived from a selective producer K2038, which produces the most effective components Bla and B2a3). Mutant K2057 produced seven different 6,8a-seco-6,8a-deoxy derivatives of avermectins which were structurally different from those of the mutant MA-5218. Four out of seven compounds were new compounds. The genotype of mutant K2057was aveE (furan ring formation) aveD (C-5 O-methylation) X (selective incorporation of branched-chain fatty acid) and that of mutant MA-521 8 would be aveE alone. Thus, mutant K2057 was unable to produce C-5 O-methylated and "b" components of avermectins, but did produce other avermectin-related antibiotics. Determinants other than aveE could give rise to accumulation of above-mentioned components of 6,8a-seco-6,8a-deoxy derivatives of avermectins. Since all avermectin derivatives from mutant K2057 lacked the furan ring at C-6 to C-8a, the mutation would be located in the step for furan ring formation in avermectin biosynthesis. Restoration of the avermectin production by introducing DNAfragments involved in avermectin biosynthesis from the wild type strain confirmed that the region involved in furan ring formation occurs in a 3.15kbp
Pstl fragment. Interestingly, transformants carrying 2.25 kbp Nsil/ BamRl fragment produced small amount of avermectins. Although the sequence of this region has not determined, the Nsil/BamHI fragment would not contain complete region for furan ring formation. Since mutant K2057accumulates the above-mentioned seven 6,8a-seco-6,8a-deoxy derivatives of avermectins, we can propose the following biosynthetic pathway following formation of 6,8a-seco-6,8a-deoxy-5-oxoavermectin aglycones including compound VII (6,8a-seco-6,8a-deoxy-5-oxoavermectin Bla aglycone; Fig. 5 ). The first step is the formation of a furan ring at C-6 to C-8a of the aglycone to generate 5-oxoavermectin aglycones. The second step is the reduction of C-5 keto residue to form avermectin aglycones. The final steps are two rounds ofglycosylation at C-13 and C-4' OH. In mutant K2057 lacking the furan ring forming activity, an aglycone in 6,8a~seco-6,8a-deoxy-5-oxoavermectin aglycones is reduced to form 6,8a-seco-6,8a-deoxyavermectin aglycones. The aglycones are then glycosylated at C-13 OH to form compound III (4'-deoleandrosyl-6,8a-seco-6,8a-deoxyavermectin B l a) and the second glycosylation takes place at C-4' OHto form compounds II (6,8a- seco-6,8a-deoxyavermectin Bla) and I (6,8a-seco-6,8a-deoxyavermectin B2a) . On the other hand, 6,8a-seco-6,8a-deoxy-5-oxoavermectin aglycones are glycosylated at C-13 OHwithout reduction of the keto residue to form compound IV (4'-deoleandrosyl-6,8a-seco-6,8a-deoxy-5-oxoavermectin B2a) and VI (4'-deoleandrosyl-6,8a-seco-6,8a-deoxy-5-oxoavermectin Bla). Probably, since both compounds IV and VI would not be suitable substrates for the second glycosylation at C-4' OH, disaccharide derivatives of 6,8a-seco-6,8a-deoxy-5-oxo derivatives would not be accumulated. Weassumed the biosynthetic route for the formation of compoundV to be as follows; (1) 6,8a-seco-6,8a-deoxy-5-oxoavermectin B2a aglycones would be dehydrated between C-7 OH and C-2 or C-6 protons, enolization would occur at C-5 keto residue and the 6-membered ring (C-2 to C-7) would be aromatized to form 6,8a-seco-6,8a-deoxy-2,5-didehydroavermectin B2a aglycones. (2) Two rounds of glycosylation at C-13 and C-4' OHwould take place to form compound V. The question of whether the dehydration reaction is enzymatic or spontaneous remains to be clarified.
